Bristol-Myers Squibb Company (BMY) Holdings Increased by Greytown Advisors Inc.
Greytown Advisors Inc. boosted its position in Bristol-Myers Squibb Company (NYSE:BMY) by 2.7% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 8,055 shares of the biopharmaceutical company’s stock after acquiring an additional 211 shares during the period. Greytown Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $449,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in BMY. Blue Chip Partners Inc. boosted its holdings in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the last quarter. Keel Point LLC boosted its holdings in shares of Bristol-Myers Squibb by 0.3% in the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 18 shares during the last quarter. Staley Capital Advisers Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.3% during the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after acquiring an additional 24 shares in the last quarter. Shayne & CO. LLC lifted its holdings in shares of Bristol-Myers Squibb by 0.6% during the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 24 shares in the last quarter. Finally, Greenleaf Trust lifted its holdings in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock valued at $535,000 after acquiring an additional 39 shares in the last quarter. 69.14% of the stock is owned by hedge funds and other institutional investors.
Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $61.91 on Wednesday. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The stock has a market cap of $100,951.66, a P/E ratio of 20.84, a PEG ratio of 2.43 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.77 EPS. analysts forecast that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were paid a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.52%. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.
BMY has been the topic of several recent research reports. Hilliard Lyons lowered shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price on the stock. in a report on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $65.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th. Barclays PLC lifted their target price on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. Jefferies Group LLC lifted their price target on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Finally, Piper Jaffray Companies set a $60.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $64.93.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Holdings Increased by Greytown Advisors Inc.” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/11/08/bristol-myers-squibb-company-bmy-holdings-increased-by-greytown-advisors-inc.html.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.23% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.